6580 Stock Overview
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
TaiRx, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$38.35 |
52 Week High | NT$42.45 |
52 Week Low | NT$23.20 |
Beta | 0.61 |
1 Month Change | 51.58% |
3 Month Change | 60.13% |
1 Year Change | 16.04% |
3 Year Change | 27.83% |
5 Year Change | 58.24% |
Change since IPO | -32.76% |
Recent News & Updates
Shareholder Returns
6580 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -2.5% | -1.1% | -0.6% |
1Y | 16.0% | -21.5% | 29.2% |
Price Volatility
6580 volatility | |
---|---|
6580 Average Weekly Movement | 14.6% |
Biotechs Industry Average Movement | 4.8% |
Market Average Movement | 4.7% |
10% most volatile stocks in TW Market | 8.7% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6580's share price has been volatile over the past 3 months.
Volatility Over Time: 6580's weekly volatility has increased from 8% to 15% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | n/a | Chien Du-Shieng | www.trx.com.tw |
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis.
TaiRx, Inc. Fundamentals Summary
6580 fundamental statistics | |
---|---|
Market cap | NT$4.23b |
Earnings (TTM) | -NT$212.29m |
Revenue (TTM) | NT$5.08m |
831.6x
P/S Ratio-19.9x
P/E RatioIs 6580 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6580 income statement (TTM) | |
---|---|
Revenue | NT$5.08m |
Cost of Revenue | NT$2.64m |
Gross Profit | NT$2.44m |
Other Expenses | NT$214.73m |
Earnings | -NT$212.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.93 |
Gross Margin | 47.99% |
Net Profit Margin | -4,177.33% |
Debt/Equity Ratio | 0% |
How did 6580 perform over the long term?
See historical performance and comparison